Climb Bio
CLYM
29 hedge funds and large institutions have $45.7M invested in Climb Bio in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 18 closing their positions.
8.97% less ownership
Funds ownership: 65.91% → 56.94% (-9%)
33% less funds holding
Funds holding: 43 → 29 (-14)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
69% less capital invested
Capital invested by funds: $147M → $45.7M (-$101M)
72% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 18
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.96M |
| 2 |
Millennium Management
New York
|
+$426K |
| 3 |
E
Ergoteles
New York
|
+$125K |
| 4 |
AI
Atom Investors
Austin,
Texas
|
+$124K |
| 5 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$17.9M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.91M |
| 3 |
BlackRock
New York
|
-$1.45M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.19M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$839K |
CLYM Hedge Fund Activity: Q2 2022 in Review
29 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q2 2022, worth a combined $45.7M — down 69% from $147M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CLYM and 5 opened new positions — a net loss of 13 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Silverarc Capital Management, adding an estimated $2.96M. The largest seller was Samlyn Capital, exiting entirely with an estimated $17.9M sold.
- 29 institutional investors held Climb Bio (CLYM) as of Q2 2022, down from 43 in Q1 2022.
- Funds reported $45.7M of Climb Bio stock for Q2 2022, down 69% quarter-over-quarter.
- 5 funds opened new Climb Bio positions in Q2 2022 and 18 closed out, a net change of -13 holders.
- The largest Climb Bio buyer in Q2 2022 was Silverarc Capital Management, an estimated $2.96M added.
- The largest Climb Bio seller in Q2 2022 was Samlyn Capital, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2022.